On May 12, 2025, the current administration published Executive Order 14297, “Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients” which generally, among other things, directs the federal government to establish and communicate most-favored-nation (“MFN”) price targets to pharmaceutical manufacturers to bring prices for American patients in line with comparably developed nations.
All entries for: BridgeBio Pharma, Inc
February 24, 2026
BridgeBio Pharma, Inc
Neutral Outlook
Palo Alto, CA
501-1,000 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Cardiology, Endocrinology, Metabolic Diseases, Neurological Diseases, Rare Diseases
Drug Type: Small Molecule